MedTrace Logo

e-ITAG Allergen Immunotherapy in the Management of Allergic Asthma

NCT06021912 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2023-09-01

No results posted yet for this study

Summary

Allergy is defined as a specific abnormal and excessive reaction of the immune system to exposed allergen .

This reaction is reproducible with each new exposure allergen . A recent study by The European Academy of Allergy and Clinical Immunology" (EAACI) estimates that 30% of the population suffers from allergic rhinitis and/or conjunctivitis, 20% of children suffer from asthma, and 8% of the population suffers from food allergies in Europe, with a clear increase in prevalence.

Allergenic immunotherapy (AIT) remains a corner stone in the treatment of allergic diseases. It involves administering an increasing dose of allergens to induce immunological tolerance. The efficacy and safety of ITA have already been demonstrated. However, patient response is highly heterogeneous. This findinf illustrates the value of biomarkers in the selection of patients, enabling prediction of response to ITA and follow-up.

Conditions

  • Study the Efficacy of ITA in Patients With Allergic Asthma or Allergic Rhinitis or Allergic Rhinitis Compared With Conventional Treatment

Interventions

DRUG

Immunotherapy

Sublingual immunotherapy

Sponsors & Collaborators

  • General Administration of Military Health, Tunisia

    lead NETWORK

Principal Investigators

  • SELSABIL DABOUSSI, MD · Pneumologie

Eligibility

Min Age
5 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-01
Primary Completion
2023-12-30
Completion
2024-03-30
FDA Drug
Yes

Countries

  • Tunisia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06021912 on ClinicalTrials.gov